Around 93% of Australian pancreatic cancer patients will die within five years of their initial diagnosis. Despite pancreatic cancer's very low survival rate, it receives less funding and research attention than other cancers. What is known is that pancreatic cancer cells often develop resistance to currently available clinical drugs. Working as part of a small University of Sydney team, Sumit hopes to develop a novel therapeutic approach to defeating advanced and drug-resistant pancreatic cancers. This grant will enable Sumit to generate proof-of-principle data for comprehensive future pre-clinical and clinical studies – and hopefully take a major step towards finding a cure.